Full text

Turn on search term navigation

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Pseudomonas aeruginosa (Pa), a WHO priority 1 pathogen, resulted in approximately 559,000 deaths globally in 2019. Pa has a multitude of host-immune evasion strategies that enhance Pa virulence. Most clinical isolates of Pa are infected by a phage called Pf that has the ability to misdirect the host-immune response and provide structural integrity to biofilms. Previous studies demonstrate that vaccination against the coat protein (CoaB) of Pf4 virions can assist in the clearance of Pa from the dorsal wound model in mice. Here, a consensus peptide was derived from CoaB and conjugated to cross-reacting material 197 (CRM197). This conjugate was adjuvanted with a novel synthetic Toll-like receptor agonist (TLR) 4 agonist, INI-2002, and used to vaccinate mice. Mice vaccinated with CoaB-CRM conjugate and INI-2002 developed high anti-CoaB peptide-specific IgG antibody titers. Direct binding of the peptide-specific antibodies to whole-phage virus particles was demonstrated by ELISA. Furthermore, a functional assay demonstrated that antibodies generated from vaccinated mice disrupted the replicative cycle of Pf phages. The use of an adjuvanted phage vaccine targeting Pa is an innovative vaccine strategy with the potential to become a new tool targeting multi-drug-resistant Pa infections in high-risk populations.

Details

Title
Adjuvanted Vaccine Induces Functional Antibodies against Pseudomonas aeruginosa Filamentous Bacteriophages
Author
Román-Cruz, Valery C 1 ; Miller, Shannon M 2 ; Schoener, Roman A 2 ; Chase Lukasiewicz 3 ; Schmidt, Amelia K 4 ; DeBuysscher, Blair L 3 ; Burkhart, David 5 ; Secor, Patrick R 1 ; Evans, Jay T 6   VIAFID ORCID Logo 

 Division of Biological Sciences, University of Montana, Missoula, MT 59812, USA; [email protected] (V.C.R.-C.); [email protected] (A.K.S.); [email protected] (P.R.S.); Center for Translational Medicine, University of Montana, Missoula, MT 59812, USA; [email protected] (C.L.); [email protected] (B.L.D.); [email protected] (D.B.) 
 Inimmune Corporation, Missoula, MT 59802, USA; [email protected] (S.M.M.); [email protected] (R.A.S.) 
 Center for Translational Medicine, University of Montana, Missoula, MT 59812, USA; [email protected] (C.L.); [email protected] (B.L.D.); [email protected] (D.B.); Department of Biomedical & Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA 
 Division of Biological Sciences, University of Montana, Missoula, MT 59812, USA; [email protected] (V.C.R.-C.); [email protected] (A.K.S.); [email protected] (P.R.S.) 
 Center for Translational Medicine, University of Montana, Missoula, MT 59812, USA; [email protected] (C.L.); [email protected] (B.L.D.); [email protected] (D.B.); Inimmune Corporation, Missoula, MT 59802, USA; [email protected] (S.M.M.); [email protected] (R.A.S.); Department of Biomedical & Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA 
 Division of Biological Sciences, University of Montana, Missoula, MT 59812, USA; [email protected] (V.C.R.-C.); [email protected] (A.K.S.); [email protected] (P.R.S.); Center for Translational Medicine, University of Montana, Missoula, MT 59812, USA; [email protected] (C.L.); [email protected] (B.L.D.); [email protected] (D.B.); Inimmune Corporation, Missoula, MT 59802, USA; [email protected] (S.M.M.); [email protected] (R.A.S.); Department of Biomedical & Pharmaceutical Sciences, University of Montana, Missoula, MT 59812, USA 
First page
115
Publication year
2024
Publication date
2024
Publisher
MDPI AG
e-ISSN
2076393X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2931099146
Copyright
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.